MY184076A - Hpv chimaeric particle - Google Patents

Hpv chimaeric particle

Info

Publication number
MY184076A
MY184076A MYPI2014700894A MYPI2014700894A MY184076A MY 184076 A MY184076 A MY 184076A MY PI2014700894 A MYPI2014700894 A MY PI2014700894A MY PI2014700894 A MYPI2014700894 A MY PI2014700894A MY 184076 A MY184076 A MY 184076A
Authority
MY
Malaysia
Prior art keywords
hpv
chimaeric
particle
vlp
relates
Prior art date
Application number
MYPI2014700894A
Other languages
English (en)
Inventor
Peter Rybicki Edward
Isabel Hitzeroth Inga
Original Assignee
Univ Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cape Town filed Critical Univ Cape Town
Publication of MY184076A publication Critical patent/MY184076A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2014700894A 2011-12-01 2012-12-03 Hpv chimaeric particle MY184076A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201108841 2011-12-01
PCT/IB2012/056912 WO2013080187A1 (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Publications (1)

Publication Number Publication Date
MY184076A true MY184076A (en) 2021-03-17

Family

ID=48534756

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014700894A MY184076A (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Country Status (18)

Country Link
US (1) US9771397B2 (cg-RX-API-DMAC7.html)
EP (1) EP2785842A4 (cg-RX-API-DMAC7.html)
JP (1) JP6228922B2 (cg-RX-API-DMAC7.html)
KR (1) KR102013801B1 (cg-RX-API-DMAC7.html)
CN (1) CN103890177B (cg-RX-API-DMAC7.html)
AU (1) AU2012345443B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012491A2 (cg-RX-API-DMAC7.html)
CA (1) CA2850293C (cg-RX-API-DMAC7.html)
HK (1) HK1198703A1 (cg-RX-API-DMAC7.html)
IL (1) IL232584B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03054A (cg-RX-API-DMAC7.html)
MX (1) MX355352B (cg-RX-API-DMAC7.html)
MY (1) MY184076A (cg-RX-API-DMAC7.html)
PH (1) PH12014500466A1 (cg-RX-API-DMAC7.html)
RU (1) RU2642287C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201401579UA (cg-RX-API-DMAC7.html)
WO (1) WO2013080187A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403557B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795906C (en) 2009-04-13 2019-02-26 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN120617536A (zh) 2013-09-18 2025-09-12 奥拉生物科学公司 用于诊断和治疗肿瘤的病毒样颗粒缀合物
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN105801704B (zh) * 2014-12-31 2020-06-02 艾托金生物医药（苏州）有限公司 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
WO2017031363A2 (en) 2015-08-18 2017-02-23 Aspyrian Therapeutics, Inc. Methods for manufacturing phthalocyanine dye conjugates and stable conjugates
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
BR112018008783A8 (pt) 2015-10-30 2019-02-26 Aleta Biotherapeutics Inc terapia-alvo de câncer
IL302880A (en) * 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
KR102797824B1 (ko) 2017-06-23 2025-04-17 버이뮨 아이엔씨. 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
KR20210110321A (ko) 2018-12-27 2021-09-07 버이뮨 아이엔씨. 접합된 바이러스-유사 입자 및 항-종양 면역 재유도제로서의 이의 용도
HUE071793T2 (hu) 2019-07-19 2025-09-28 Sinocelltech Ltd Polivalens immunogén készítmény humán papillomavírusra
WO2021161179A1 (en) * 2020-02-10 2021-08-19 University Of Cape Town Plant produced bovine papillomavirus virus-like particles and pseudovirions
KR20230129379A (ko) 2020-10-19 2023-09-08 버이뮨 아이엔씨. 바이러스에 영향받은 조성물 및 암 치료를 위해 이를 사용하여 기존 면역 반응을 재지향시키는 방법
KR102821363B1 (ko) 2023-02-06 2025-06-13 영산대학교산학협력단 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183781B1 (pl) * 1994-05-16 2002-07-31 Merck & Co Inc Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
ATE324436T1 (de) 1998-08-14 2006-05-15 Merck & Co Inc Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
WO2003068933A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
JP4614765B2 (ja) 2002-05-17 2011-01-19 ユニバーシティ・オブ・ケープ・タウン Ｌ２ペプチドを含むキメラ・ヒト・パピローマウイルス１６ｌ１タンパク質、それから調製したウイルス様粒子および該粒子の調製方法
ES2381200T3 (es) 2005-04-29 2012-05-24 University Of Cape Town Expresión de proteínas virales en las plantas
BRPI1013895B1 (pt) * 2009-04-10 2021-08-03 The Johns Hopkins University Composições de partícula semelhante a virus (vlp) de virus do papiloma e de capsómero, método de preparação das mesmas, vacina compreendendo a referida composição vlp, polipeptídeo quimérico, kit compreendendo a reverida composição de vlp, bem com usos da referida vlp
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
AU2010264695A1 (en) 2009-06-25 2012-01-19 Glaxosmithkline Biologicals S.A. Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
WO2011077371A1 (en) * 2009-12-22 2011-06-30 University Of Cape Town Method for enhancing the expression of hpv l1

Also Published As

Publication number Publication date
RU2014126587A (ru) 2016-01-27
JP2015500229A (ja) 2015-01-05
CN103890177B (zh) 2016-03-09
HK1198703A1 (en) 2015-05-29
CA2850293C (en) 2019-10-08
BR112014012491A2 (pt) 2017-06-06
WO2013080187A1 (en) 2013-06-06
AU2012345443A1 (en) 2014-04-17
EP2785842A4 (en) 2015-11-25
SG11201401579UA (en) 2014-07-30
US20140377367A1 (en) 2014-12-25
CN103890177A (zh) 2014-06-25
MX2014006520A (es) 2014-11-21
MX355352B (es) 2018-04-17
IN2014DN03054A (cg-RX-API-DMAC7.html) 2015-05-15
AU2012345443B2 (en) 2017-10-26
PH12014500466A1 (en) 2022-05-11
US9771397B2 (en) 2017-09-26
KR20140098061A (ko) 2014-08-07
IL232584A0 (en) 2014-06-30
EP2785842A1 (en) 2014-10-08
JP6228922B2 (ja) 2017-11-08
ZA201403557B (en) 2020-10-28
IL232584B (en) 2018-10-31
RU2642287C2 (ru) 2018-01-24
KR102013801B1 (ko) 2019-08-23
NZ622595A (en) 2016-04-29
CA2850293A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
MY184076A (en) Hpv chimaeric particle
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
HK1246183A1 (zh) Hpv疫苗
MX2022007522A (es) Anticuerpos anti-cd27.
MX2022001105A (es) Anticuerpos anti tigit.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX361218B (es) Análogos de spliceostatina.
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014500724A1 (en) Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3010507A4 (en) Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
IN2011CH03893A (cg-RX-API-DMAC7.html)
WO2013093629A3 (en) Modular vaccines, methods and compositions related thereto
PH12017500928B1 (en) A rabies composition comprising pika adjuvant
IN2014DN10683A (cg-RX-API-DMAC7.html)
WO2011054996A3 (es) Vacunas para el tratamiento de neoplasias a partir de capsides virales de birnavirus conteniendo antigenos del virus del papiloma humano
UA90646C2 (ru) Способ лечения часто рецидивирующей хронической герпетической инфекции, вызванной вирусом герпеса простого и и ии типов
UA74055U (ru) Способ хирургического лечения рефрактерных форм глаукомы
UA59657U (ru) Способ лечения женщин с фоновыми заболеваниями шейки матки на фоне генитальной герпесвирусной инфекции
UA55818U (ru) Способ лечения хронических заболеваний роговицы